DNA methylation profiles in ovarian cancer: Implication in diagnosis and therapy (Review)

Molecular Medicine Reports

Volumn 10, Issue 1, 2014, Pages 3-9

  Koukoura, Ourania ^a   Spandidos, Demetrios A ^b   Daponte, Alexandros ^a   Sifakis, Stavros ^c  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Biomarkers; DNA methylation; Epigenetic mechanisms; Oncogenes; Ovarian cancer; Tumor suppressor genes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CADHERIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; H CADHERIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN PMS2; PLATINUM; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SECRETED FRIZZLED RELATED PROTEIN 5; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; UVOMORULIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; ENZYME INHIBITOR;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL CYCLE REGULATION; CPG ISLAND; DNA FINGERPRINTING; DNA METHYLATION; DNA REPAIR; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HOX GENE; HUMAN; MISMATCH REPAIR; NONHUMAN; OVARY CANCER; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; REVIEW; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; OVARIAN NEOPLASMS;

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS;

EID: 84901436722     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2221     Document Type: Review

References (97)

1. Hennessy BT, Coleman RL and Markman M: Ovarian cancer. Lancet 374: 1371-1382, 2009.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Bookman MA, Brady MF, McGuire WP, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27: 1419-1425, 2009.
4. Claus EB, Schildkraut JM, Thompson WD and Risch NJ: The genetic attributable risk of breast and ovarian cancer. Cancer 77: 2318-2324, 1996. (Pubitemid 26162426)
5. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117-1130, 2003. (Pubitemid 36530000)
6. Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H and DeLoia JA: Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 124: 575-581, 2012.
7. Darcy KM, Brady WE, Blancato JK, Dickson RB, Hoskins WJ, McGuire WP and Birrer MJ: Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol 114: 472-479, 2009.
8. Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E and Camilleri-Broët S: HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2: e1138, 2007
9. Baylin SB and Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116, 2006. (Pubitemid 43361543)
10. Ushijima T and Asada K: Aberrant DNA methylation in contrast with mutations. Cancer Sci 101: 300-305, 2010.
11. Yoo CB and Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50, 2006.
12. Russo VEA, Riggs AD and Martienssen RA: Epigenetic mechanisms of gene regulation. Cold Spring Harbor Laboratory Press, Plainview, NY, 1996.
13. Jones PA and Baylin SB: The epigenomics of cancer. Cell 128: 683-692, 2007. (Pubitemid 46273572)
14. Wilting RH and Dannenberg JH: Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat 15: 21-38, 2012.
15. Koukoura O, Sifakis S and Spandidos DA: DNA methylation in the human placenta and fetal growth (Review). Mol Med Rep 5: 883-839, 2012.
16. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003. (Pubitemid 37448928)
17. Weber M and Schubeler D: Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Curr Opin Cell Biol 19: 273-280, 2007. (Pubitemid 46899512)
18. Bird AP and Wolffe AP: Methylation-induced repression - belts, braces, and chromatin. Cell 99: 451-454, 1999. (Pubitemid 129746827)
19. Costello JF and Plass C: Methylation matters. J Med Genet 38: 285-303, 2001. (Pubitemid 32433981)
20. Catteau A, Harris WH, Xu CF and Solomon E: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18: 1957-1965, 1999. (Pubitemid 29150082)
21. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148-1159, 2008.
22. Esteller M, Silva JM, Dominguez G, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92: 564-569, 2000. (Pubitemid 30212318)
23. Baylin SB and Chen WY: Aberrant gene silencing in tumor progression: implications for control of cancer. Cold Spring Harb Symp Quant Biol 70: 427-433, 2005. (Pubitemid 44124898)
24. Horak P, Pils D, Haller G, et al: Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 3: 335-343, 2005. (Pubitemid 40905625)
25. Petrocca F, Iliopoulos D, Qin HR, et al: Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res 66: 10287-10291, 2006. (Pubitemid 44799746)
26. Yu Y, Fujii S, Yuan J, et al: Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann NY Acad Sci 983: 268-277, 2003. (Pubitemid 36399339)
27. Baldwin RL, Nemeth E, Tran H, et al: BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60: 5329-5333, 2000.
28. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B and Buller RE: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94: 1396-1406, 2002. (Pubitemid 35154144)
29. Li ML and Greenberg RA: Links between genome integrity and BRCA1 tumor suppression. Trends Biochem Sci 37: 418-424, 2012.
30. McCoy ML, Mueller CR and Roskelley CD: The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reprod Biol Endocrinol 1: 72, 2003.
31. Rzepecka IK, Szafron L, Stys A, et al: High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. Cancer Genet 205: 94-100, 2012.
32. Strathdee G, Appleton K, Illand M, et al: Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158: 1121-1127, 2001. (Pubitemid 32221804)
33. Chan KY, Ozcelik H, Cheung AN, Ngan HY and Khoo US: Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 62: 4151-4156, 2002. (Pubitemid 34791087)
34. Wang YQ, Yan Q, Zhang JR, Li SD, Yang YX and Wan XP: Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression. J Obstet Gynaecol Res 39: 549-554, 2013.
35. Wang C, Horiuchi A, Imai T, et al: Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 202: 215-223, 2004. (Pubitemid 38208659)
36. Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan HY: Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6: 212, 2006.
37. Bol GM, Suijkerbuijk KP, Bart J, Vooijs M, van der Wall E and van Diest PJ: Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology 57: 363-370, 2010.
38. Rathi A, Virmani AK, Schorge JO, et al: Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8: 3324-3331, 2002. (Pubitemid 35340705)
39. Kontorovich T, Cohen Y, Nir U and Friedman E: Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat 116: 195-200, 2009.
40. Blasi MF, Ventura I, Aquilina G, et al: A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene. Cancer Res 66: 9036-9044, 2006. (Pubitemid 44521122)
41. Jiricny J and Nyström-Lahti M: Mismatch repair defects in cancer. Curr Opin Genet Dev 10: 157-161, 2000. (Pubitemid 30182248)
42. Kunkel TA and Erie DA: DNA mismatch repair. Annu Rev Biochem 74: 681-710, 2005. (Pubitemid 40995521)
43. Murphy MA and Wentzensen N: Frequency of mismatch repair deficiency in ovarian cancer: a systematic review. This article is a US Government work and, as such, is in the public domain of the United States of America. Int J Cancer 129: 1914-1922, 2011.
44. Zhang H, Zhang S, Cui J, Zhang A, Shen L and Yu H: Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Aust N Z J Obstet Gynaecol 48: 505-509, 2008.
45. Watanabe Y, Ueda H, Etoh T, et al: A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res 27: 1449-1452, 2007. (Pubitemid 46807221)
46. Barton CA, Hacker NF, Clark SJ and O'Brien PM: DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 109: 129-139, 2008.
47. Ozdemir F, Altinisik J, Karateke A, Coksuer H and Buyru N: Methylation of tumor suppressor genes in ovarian cancer. Exp Ther Med 4: 1092-1096, 2012.
48. Moselhy SS, Kumosani TA, Kamal IH, Jalal JA, Abdul Jabaar HS and Dalol A: Hypermethylation of P15, P16, and E-cadherin genes in ovarian cancer. Toxicol Ind Health: Apr 9, 2013 (Epub ahead of print).
49. Dhillon VS, Young AR, Husain SA and Aslam M: Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin. Br J Cancer 90: 874-881, 2004. (Pubitemid 38406600)
50. Staub J, Chien J, Pan Y, et al: Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene 26: 4969-4978, 2007. (Pubitemid 47172647)
51. Samuel S and Naora H: Homeobox gene expression in cancer: insights from developmental regulation and deregulation. Eur J Cancer 41: 2428-2437, 2005. (Pubitemid 41540620)
52. Kelly ZL, Michael A, Butler-Manuel S, Pandha HS and Morgan RG: HOX genes in ovarian cancer. J Ovarian Res 4: 16, 2011.
53. Montavon C, Gloss BS, Warton K, et al: Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 124: 582-588, 2012.
54. Widschwendter M, Apostolidou S, Jones AA, et al: HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. Int J Cancer 125: 2214-2218, 2009.
55. Swisher EM, Gonzalez RM, Taniguchi T, et al: Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 8: 48, 2009.
56. Ibanez de Caceres I, Battagli C, Esteller M, et al: Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 64: 6476-6481, 2004. (Pubitemid 39297903)
57. Makarla PB, Saboorian MH, Ashfaq R, et al: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11: 5365-5369, 2005. (Pubitemid 41060809)
58. Tam KF, Liu VW, Liu SS, et al: Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol 133: 331-341, 2007. (Pubitemid 46723501)
59. Pattamadilok J, Huapai N, Rattanatanyong P, et al: LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer 18: 711-717, 2008. (Pubitemid 352020191)
60. Widschwendter M, Jiang G, Woods C, et al: DNA hypomethylation and ovarian cancer biology. Cancer Res 64: 4472-4480, 2004. (Pubitemid 38856918)
61. Honda H, Pazin MJ, Ji H, Wernyj RP and Morin PJ: Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J Biol Chem 281: 21433-21444, 2006. (Pubitemid 44115482)
62. Lee PS, Teaberry VS, Bland AE, et al: Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer 126: 1378-1389, 2010.
63. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K and Karpf AR: DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 7: 21, 2007.
64. Izutsu N, Maesawa C, Shibazaki M, et al: Epigenetic modification is involved in aberrant expression of class III β-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol 32: 1227-1235, 2008.
65. Balch C, Matei DE, Huang TH and Nephew KP: Role of epigenomics in ovarian and endometrial cancers. Epigenomics 2: 419-447, 2010.
66. Strathdee G, Davies BR, Vass JK, Siddiqui N and Brown R: Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. Carcinogenesis 25: 693-701, 2004. (Pubitemid 38618520)
67. Strathdee G, Vass JK, Oien KA, Siddiqui N, Curto-Garcia J and Brown R: Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol 97: 898-903, 2005. (Pubitemid 40824663)
68. Gupta A, Godwin AK, Vanderveer L, Lu A and Liu J: Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 63: 664-673, 2003. (Pubitemid 36158146)
69. Teschendorff AE, Menon U, Gentry-Maharaj A, et al: An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One 4: e8274, 2009.
70. Wei SH, Balch C, Paik HH, et al: Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12: 2788-2794, 2006.
71. Wei SH, Chen CM, Strathdee G, et al: Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8: 2246-2252, 2002. (Pubitemid 34753597)
72. Zhang Q, Hu G, Yang Q, et al: A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol 130: 132-139, 2013.
73. Melnikov A, Zaborina O, Dhiman N, Prabhakar BS, Chakrabarty AM and Hendrickson W: Clinical and environmental isolates of Burkholderia cepacia exhibit differential cytotoxicity towards macrophages and mast cells. Mol Microbiol 36: 1481-1493, 2000. (Pubitemid 30449982)
74. Ozols RF: Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33: S3-S11, 2006.
75. Balch C, Huang TH, Brown R and Nephew KP: The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191: 1552-1572, 2004. (Pubitemid 39491180)
76. Su HY, Lai HC, Lin YW, et al: Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 127: 555-567, 2010.
77. Nicholson LJ, Smith PR, Hiller L, et al: Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer 125: 1454-1463, 2009.
78. Strathdee G, MacKean MJ, Illand M and Brown R: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335-2341, 1999. (Pubitemid 29192710)
79. Yap OW, Bhat G, Liu L and Tollefsbol TO: Epigenetic modifications of the estrogen receptor beta gene in epithelial ovarian cancer cells. Anticancer Res 29: 139-144, 2009.
80. Lehmann U, Celikkaya G, Hasemeier B, Langer F and Kreipe H: Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 62: 6634-6638, 2002. (Pubitemid 35364131)
81. Curley MD, Therrien VA, Cummings CL, et al: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27: 2875-2883, 2009.
82. Li M, Balch C, Montgomery JS, et al: Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2: 34, 2009.
83. Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266, 2003.
84. Ivanov M, Kacevska M and Ingelman-Sundberg M: Epigenomics and interindividual differences in drug response. Clin Pharmacol Ther 92: 727-736, 2012.
85. Santi DV, Norment A and Garrett CE: Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 81: 6993-6997, 1984. (Pubitemid 15216684)
86. Kaminskas E, Farrell A, Abraham S, et al: Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11: 3604-3608, 2005. (Pubitemid 40685574)
87. Issa JP, Garcia-Manero G, Giles FJ, et al: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640, 2004. (Pubitemid 38268953)
88. Issa JP, Gharibyan V, Cortes J, et al: Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23: 3948-3956, 2005. (Pubitemid 46218698)
89. Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y and Dahiya R: Hypermethylation can selectively silence multiple promoters of steroid receptors in cancers. Mol Cell Endocrinol 202: 201-207, 2003. (Pubitemid 36593413)
90. Takai N, Kawamata N, Walsh CS, et al: Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol Cancer Res 3: 261-269, 2005. (Pubitemid 40656813)
91. Plumb JA, Strathdee G, Sludden J, Kaye SB and Brown R: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60: 6039-6044, 2000.
92. Fu S, Hu W, Iyer R, et al: Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117: 1661-1669, 2011.
93. Fang F, Balch C, Schilder J, et al: A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 116: 4043-4053, 2010.
94. Chen H, Hardy TM and Tollefsbol TO: Epigenomics of ovarian cancer and its chemoprevention. Front Genet 2: 67, 2011.
95. Terasawa K, Sagae S, Toyota M, et al: Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 10: 2000-2006, 2004. (Pubitemid 38375559)
96. Shi H, Wei SH, Leu YW, et al: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res 63: 2164-2171, 2003. (Pubitemid 36538622)
97. Appleton K, Mackay HJ, Judson I, et al: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25: 4603-4609, 2007. (Pubitemid 350035319)